StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — U.S. Revenue ($M) ($M)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

QuarterlyAnnual
Latest, Q4 2025
445
Period ended Dec 31, 2025
Change on a year earlier
-19.7%
554 in Q4 2024
History
33 quarters
Since Q4 2017
Sources
29
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — U.S. Revenue ($M) ($M)Year on yearSource
Q4 2025Dec 31, 2025445-19.7%SEC Filing (0001628280-26-002982) ↗
Q3 2025Sep 30, 2025373-33.4%SEC Filing (0001628280-25-045049) ↗
Q2 2025Jun 30, 2025321-7.0%SEC Filing (0001628280-25-035135) ↗
Q1 2025Mar 31, 2025399-17.0%SEC Filing (0001628280-25-017924) ↗
Q4 2024Dec 31, 2024554+2.0%SEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 2024560-0.2%SEC Filing (0001628280-24-042893) ↗
Q2 2024Jun 30, 2024345-32.1%SEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 2024481-46.9%SEC Filing (0001628280-24-016497) ↗
Q4 2023Dec 31, 2023543-55.3%SEC Filing (0001628280-25-002092) ↗
Q3 2023Sep 30, 2023561-55.9%SEC Filing (0001628280-24-042893) ↗
Q2 2023Jun 30, 2023508-74.4%SEC Filing (0001628280-24-032182) ↗
Q1 2023Mar 31, 2023906-58.5%SEC Filing (0001628280-24-016497) ↗
Q4 2022Dec 31, 20221,216-34.5%SEC Filing (0001628280-24-002009) ↗
Q3 2022Sep 30, 20221,273-8.7%SEC Filing (0001628280-23-034544) ↗
Q2 2022Jun 30, 20221,982+191.0%SEC Filing (0001628280-23-025156) ↗
Q1 2022Mar 31, 20222,181+97.7%SEC Filing (0001628280-23-012020) ↗

Breakdown

What makes up rapid diagnostics (legacy standalone subsegment through fy2025q4 — id now, binaxnow, panbio) — u.s. revenue ($m)

Cite this data

StockData. (2026). Abbott Laboratories Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — U.S. Revenue ($M) ($M), quarterly Q4 2017–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rapid-leg-rev-us

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.